Response to treatment
| . | PAdriaCEBO, no. (%) . | PMitCEBO, no. (%) . | P value . |
|---|---|---|---|
| CR | 125 (52) | 137 (60) | .12 |
| ICRD | 1 (< 1) | 1 (< 1) | |
| PPR | 18 (8) | 16 (7) | |
| NPPR | 24 (10) | 26 (11) | |
| ORR | 168 (69) | 180 (78) | .05 |
| NR | 72 (30) | 50 (22) | |
| NE* | 3 | ||
| Total | 243 | 230 |
| . | PAdriaCEBO, no. (%) . | PMitCEBO, no. (%) . | P value . |
|---|---|---|---|
| CR | 125 (52) | 137 (60) | .12 |
| ICRD | 1 (< 1) | 1 (< 1) | |
| PPR | 18 (8) | 16 (7) | |
| NPPR | 24 (10) | 26 (11) | |
| ORR | 168 (69) | 180 (78) | .05 |
| NR | 72 (30) | 50 (22) | |
| NE* | 3 | ||
| Total | 243 | 230 |
ICRD indicates in complete remission death; PPR, progressive partial response; NPPR, nonprogressive partial response; ORR, overall response rate; NR, no response; NE, not evaluable.
One patient refused treatment; 2 patients were lost to follow-up.